Dong Yi Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong Yi Kim has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Seong Yeob Ryu
Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
20 shared publicationsJae Kyoon Joo
Jin Hong Kim, Jae Kyoon Joo, Seong Yeob Ryu, Ho Gun Kim, Dong Yi Kim, Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju 501-757, South Korea
14 shared publicationsJae Hyuk Lee
Department of Pathology, Chonnam National University Medical School, Gwangju
12 shared publicationsShin Kon Kim
Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
12 shared publicationsYoung Jin Kim
Division of Gastoenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
10 shared publicationsYoung Kyu Park
Division of Gastoenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
9 shared publications
Latest Publications
- Open Access
- 30 December 2022
- Published by Vilnius University Press in Lietuvos chirurgija
- Vol. 21  (3-4) , 202-207
Prognosis of Stage IV Gastric Cancer Patients
Publishes scientific surgical articles written by Lithuanian and foreign authors.
- 30 December 2022
- Published by Vilnius University Press in Lietuvos chirurgija
- Vol. 21  (3-4) , 202-207
Open AccessPrognosis of Stage IV Gastric Cancer Patients
Publishes scientific surgical articles written by Lithuanian and foreign authors.
- Open Access
- 31 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11  (21) , 6453
The Impact of Overweight and Obesity on Reduced-Port Laparoscopic Distal Gastrectomy for Gastric Cancer Patients: A Propensity Score Matching Analysis of a Single-Institution Data
This study aimed to investigate the short-term postoperative outcomes of reduced-port laparoscopic distal gastrectomy and demonstrate its safety and feasibility in overweight and obese patients with gastric cancer. The medical records of 211 patients who underwent reduced-port laparoscopic distal gastrectomy, between August 2014 and April 2020, were reviewed. After propensity score matching, they were divided into a non-overweight group (n = 68) and overweight group (n = 68). Operative details and short-term surgical outcomes were compared between two groups. Reduced-port laparoscopic distal gastrectomy in overweight group showed statistically longer operation time (200.59 vs. 208.68 min, p = 0.044), higher estimated bleeding volume (40.96 vs. 58.01 mL, p = 0.001), and lesser number of harvested lymph nodes (36.81 vs. 32.13, p = 0.039). However, no significant differences were found in hospital course and other surgical outcomes. There was no mortality in either group, and the postoperative morbidity rate was not significantly different (14.7% vs. 16.2%). In the subgroup analysis, overweight and obesity did not significantly affect postoperative complication rates (16.2% vs. 16.2%, p = 1). We demonstrated comparable short-term surgical outcomes of reduced-port laparoscopic distal gastrectomy between the two groups (p = 0.412~1). Reduced-port laparoscopic distal gastrectomy was safe in overweight and obese patients with gastric cancer.
- 31 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11  (21) , 6453
Open AccessThe Impact of Overweight and Obesity on Reduced-Port Laparoscopic Distal Gastrectomy for Gastric Cancer Patients: A Propensity Score Matching Analysis of a Single-Institution Data
This study aimed to investigate the short-term postoperative outcomes of reduced-port laparoscopic distal gastrectomy and demonstrate its safety and feasibility in overweight and obese patients with gastric cancer. The medical records of 211 patients who underwent reduced-port laparoscopic distal gastrectomy, between August 2014 and April 2020, were reviewed. After propensity score matching, they were divided into a non-overweight group (n = 68) and overweight group (n = 68). Operative details and short-term surgical outcomes were compared between two groups. Reduced-port laparoscopic distal gastrectomy in overweight group showed statistically longer operation time (200.59 vs. 208.68 min, p = 0.044), higher estimated bleeding volume (40.96 vs. 58.01 mL, p = 0.001), and lesser number of harvested lymph nodes (36.81 vs. 32.13, p = 0.039). However, no significant differences were found in hospital course and other surgical outcomes. There was no mortality in either group, and the postoperative morbidity rate was not significantly different (14.7% vs. 16.2%). In the subgroup analysis, overweight and obesity did not significantly affect postoperative complication rates (16.2% vs. 16.2%, p = 1). We demonstrated comparable short-term surgical outcomes of reduced-port laparoscopic distal gastrectomy between the two groups (p = 0.412~1). Reduced-port laparoscopic distal gastrectomy was safe in overweight and obese patients with gastric cancer.
- Open Access
- 6 June 2022
- Published by Shaukat Khanum Memorial Cancer Hospital and Research Centre in Journal of Cancer & Allied Specialties
- Vol. 8  (2) , 467
Prognosis of Elderly Patients with Advanced Gastric Cancer without Serosal Invasion
Introduction: The impact of age on the prognosis of patients with gastric cancer is controversial. This study aimed to investigate the clinicopathologic features and prognosis of elderly, advanced gastric cancer patients without serosal invasion compared to their younger counterparts. Materials and Methods: We retrospectively evaluated 43 elderly patients with advanced gastric cancer without serosal invasion. The clinicopathologic findings were compared between the elderly (age >70 years) and young (age <36 years) patients. Results: Significantly higher numbers of elderly patients had tumors with differentiated histology, whereas more young patients had tumors with undifferentiated histology (P < 0.01). Curability (risk ratio, 3.122; confidence interval, 1.242-4.779; P < 0.001) was an independent prognostic factor of survival. The 5-year survival rates were not significantly different between the elderly and the young patients according to the absence of serosal invasion (80.0% vs 77.9%; P = 0.654) and undergoing curative resection (82.0% vs 78.9%; P = 0.312). Meanwhile, among the elderly patients, those who underwent curative resection had a better survival rate than those with non-curative resection (82.0% vs 67.8%; P < 0.001). Conclusion: Elderly patients with advanced gastric cancer without serosal invasion do not have a worse prognosis than their younger counterparts, indicating that age does not impact the prognosis of advanced gastric cancer. The important prognostic factor was whether the patients underwent curative resection.
- 6 June 2022
- Published by Shaukat Khanum Memorial Cancer Hospital and Research Centre in Journal of Cancer & Allied Specialties
- Vol. 8  (2) , 467
Open AccessPrognosis of Elderly Patients with Advanced Gastric Cancer without Serosal Invasion
Introduction: The impact of age on the prognosis of patients with gastric cancer is controversial. This study aimed to investigate the clinicopathologic features and prognosis of elderly, advanced gastric cancer patients without serosal invasion compared to their younger counterparts. Materials and Methods: We retrospectively evaluated 43 elderly patients with advanced gastric cancer without serosal invasion. The clinicopathologic findings were compared between the elderly (age >70 years) and young (age <36 years) patients. Results: Significantly higher numbers of elderly patients had tumors with differentiated histology, whereas more young patients had tumors with undifferentiated histology (P < 0.01). Curability (risk ratio, 3.122; confidence interval, 1.242-4.779; P < 0.001) was an independent prognostic factor of survival. The 5-year survival rates were not significantly different between the elderly and the young patients according to the absence of serosal invasion (80.0% vs 77.9%; P = 0.654) and undergoing curative resection (82.0% vs 78.9%; P = 0.312). Meanwhile, among the elderly patients, those who underwent curative resection had a better survival rate than those with non-curative resection (82.0% vs 67.8%; P < 0.001). Conclusion: Elderly patients with advanced gastric cancer without serosal invasion do not have a worse prognosis than their younger counterparts, indicating that age does not impact the prognosis of advanced gastric cancer. The important prognostic factor was whether the patients underwent curative resection.
- Open Access
- 5 August 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16  (8) , e0255855
Reduced-port laparoscopic distal gastrectomy in obese gastric cancer patients
Background: Reduced-port laparoscopic gastrectomy is currently widely performed for patients with gastric cancer. However, its safety in obese patients has not yet been verified. This is the first study on reduced-port laparoscopic distal gastrectomy (RpLDG) in obese patients with gastric cancer. This study aimed to evaluate the short-term surgical outcomes and investigate the feasibility and safety of RpLDG in obese patients with gastric carcinoma. Material and methods: A total of 271 gastric cancer patients who underwent RpLDG at our institution were divided into two groups: non-obese [body mass index (BMI) <30 kg/m2, n = 251; NOG] and obese (BMI ≥30 kg/m2, n = 20; OG). The mean age of the enrolled patients was 64.8 ± 11.4 years, with 72.0% being men and 28.0% women. Operative details and short-term surgical outcomes, including hospital course and postoperative complications, were compared by retrospectively reviewing the medical records. Results: No significant difference in operation time was found between the NOG and OG (205.9 ± 40.0 vs. 211.3 ± 37.3 minutes, P = 0.563). Other operative outcomes in the OG, including estimated blood loss (54.1 ± 86.1 vs. 54.0 ± 39.0 mL, P = 0.995) and retrieved lymph nodes (36.2 ± 16.4 vs. 35.5 ± 18.2, P = 0.875), were not inferior to those in the NOG. There were also no statistical differences in short-term surgical outcomes, including the incidence of surgical complications (13.9% vs. 10.0%, P = 1). Conclusion: RpLDG can be performed safely in obese gastric cancer patients by an experienced surgeon. It should be considered a feasible alternative to conventional port distal gastrectomy.
- 5 August 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16  (8) , e0255855
Open AccessReduced-port laparoscopic distal gastrectomy in obese gastric cancer patients
Background: Reduced-port laparoscopic gastrectomy is currently widely performed for patients with gastric cancer. However, its safety in obese patients has not yet been verified. This is the first study on reduced-port laparoscopic distal gastrectomy (RpLDG) in obese patients with gastric cancer. This study aimed to evaluate the short-term surgical outcomes and investigate the feasibility and safety of RpLDG in obese patients with gastric carcinoma. Material and methods: A total of 271 gastric cancer patients who underwent RpLDG at our institution were divided into two groups: non-obese [body mass index (BMI) <30 kg/m2, n = 251; NOG] and obese (BMI ≥30 kg/m2, n = 20; OG). The mean age of the enrolled patients was 64.8 ± 11.4 years, with 72.0% being men and 28.0% women. Operative details and short-term surgical outcomes, including hospital course and postoperative complications, were compared by retrospectively reviewing the medical records. Results: No significant difference in operation time was found between the NOG and OG (205.9 ± 40.0 vs. 211.3 ± 37.3 minutes, P = 0.563). Other operative outcomes in the OG, including estimated blood loss (54.1 ± 86.1 vs. 54.0 ± 39.0 mL, P = 0.995) and retrieved lymph nodes (36.2 ± 16.4 vs. 35.5 ± 18.2, P = 0.875), were not inferior to those in the NOG. There were also no statistical differences in short-term surgical outcomes, including the incidence of surgical complications (13.9% vs. 10.0%, P = 1). Conclusion: RpLDG can be performed safely in obese gastric cancer patients by an experienced surgeon. It should be considered a feasible alternative to conventional port distal gastrectomy.
- Open Access
- 15 June 2021
- Published by The Korean Society of Endo-Laparoscopic & Robotic Surgery in Journal of Minimally Invasive Surgery
- Vol. 24  (2) , 76-83
Transpyloric optic navigation of tumor using a laparoscope during totally laparoscopic distal gastrectomy for gastric cancer
Sola Lee, Ho Goon Kim, Dong Yeon Kang, Dong Yi Kim, Seong Yeob Ryu. Journal of Minimally Invasive Surgery 2021;24:76-83. https://doi.org/10.7602/jmis.2021.24.2.76
- 15 June 2021
- Published by The Korean Society of Endo-Laparoscopic & Robotic Surgery in Journal of Minimally Invasive Surgery
- Vol. 24  (2) , 76-83
Open AccessTranspyloric optic navigation of tumor using a laparoscope during totally laparoscopic distal gastrectomy for gastric cancer
Sola Lee, Ho Goon Kim, Dong Yeon Kang, Dong Yi Kim, Seong Yeob Ryu. Journal of Minimally Invasive Surgery 2021;24:76-83. https://doi.org/10.7602/jmis.2021.24.2.76
- Open Access
Hyaluronic Acid-Based Nanomaterials for Cancer Therapy
Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan and a major component of the extracellular matrix. HA is overexpressed by numerous tumor cells, especially tumor-initiating cells. HA-based nanomaterials play in importance role in drug delivery systems. HA is used in various types of nanomaterials including micelle, polymersome, hydrogel, and inorganic nanoparticle formulations. Many experiments show that HA-based nanomaterials can serve as a platform for targeted chemotherapy, gene therapy, immunotherapy, and combination therapy with good potential for future biomedical applications in cancer treatment.
Open AccessHyaluronic Acid-Based Nanomaterials for Cancer Therapy
Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan and a major component of the extracellular matrix. HA is overexpressed by numerous tumor cells, especially tumor-initiating cells. HA-based nanomaterials play in importance role in drug delivery systems. HA is used in various types of nanomaterials including micelle, polymersome, hydrogel, and inorganic nanoparticle formulations. Many experiments show that HA-based nanomaterials can serve as a platform for targeted chemotherapy, gene therapy, immunotherapy, and combination therapy with good potential for future biomedical applications in cancer treatment.
- Open Access
- 1 January 2018
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 95  (2) , 55-63
Quantitative analysis ofCOX-2promoter methylation in gastric carcinoma
Kim HG, et al. Ann Surg Treat Res. 2018 Aug;95(2):55-63. https://doi.org/10.4174/astr.2018.95.2.55
- 1 January 2018
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 95  (2) , 55-63
Open AccessQuantitative analysis ofCOX-2promoter methylation in gastric carcinoma
Kim HG, et al. Ann Surg Treat Res. 2018 Aug;95(2):55-63. https://doi.org/10.4174/astr.2018.95.2.55
- Open Access
- 1 January 2018
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 18  (2) , 172-181
Transition from Conventional to Reduced-Port Laparoscopic Gastrectomy to Treat Gastric Carcinoma: a Single Surgeon's Experience from a Small-Volume Center
Kim HG, et al. J Gastric Cancer. 2018 Apr;18:e18. https://doi.org/10.5230/jgc.2018.18.e18
- 1 January 2018
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 18  (2) , 172-181
Open AccessTransition from Conventional to Reduced-Port Laparoscopic Gastrectomy to Treat Gastric Carcinoma: a Single Surgeon's Experience from a Small-Volume Center
Kim HG, et al. J Gastric Cancer. 2018 Apr;18:e18. https://doi.org/10.5230/jgc.2018.18.e18
- Open Access
- 1 January 2018
- Published by Chonnam National University Medical School in Chonnam Medical Journal
- Vol. 54  (1) , 36-40
The Benefits of Resection for Gastric Carcinoma Patients with Non-curative Factors
The benefits of resection for gastric carcinoma patients with non-curative factors remain controversial. Thus, we evaluated the survival benefits of resection in these gastric carcinoma patients. We reviewed the hospital records of 467 gastric carcinoma patients with non-curative factors who had resection (n=305) and compared their clinicopathological findings with individuals (n=162) who underwent bypass or exploration from 1996 to 2010. The 3-year survival rate of patients who had resection was higher than was that of patients who did not (13.2 vs. 7.2%, respectively p<0.001). Cox's proportional hazard regression analysis revealed that only one factor was an independent, statistically significant prognostic parameter: the presence of peritoneal dissemination (risk ratio, 1.37; 95% confidence interval, 1.04–1.79; p<0.05). The 3-year survival rate of patients with peritoneal dissemination was higher in individuals who underwent resection compared with those who did not (9.5 vs. 4.7%, respectively; p<0.001). The current results highlight the improved survival rates of gastric carcinoma patients with non-curative factors who underwent surgery compared with those who did not. Although resection is not curative in this group of patients, we still recommend performing the procedure.
- 1 January 2018
- Published by Chonnam National University Medical School in Chonnam Medical Journal
- Vol. 54  (1) , 36-40
Open AccessThe Benefits of Resection for Gastric Carcinoma Patients with Non-curative Factors
The benefits of resection for gastric carcinoma patients with non-curative factors remain controversial. Thus, we evaluated the survival benefits of resection in these gastric carcinoma patients. We reviewed the hospital records of 467 gastric carcinoma patients with non-curative factors who had resection (n=305) and compared their clinicopathological findings with individuals (n=162) who underwent bypass or exploration from 1996 to 2010. The 3-year survival rate of patients who had resection was higher than was that of patients who did not (13.2 vs. 7.2%, respectively p<0.001). Cox's proportional hazard regression analysis revealed that only one factor was an independent, statistically significant prognostic parameter: the presence of peritoneal dissemination (risk ratio, 1.37; 95% confidence interval, 1.04–1.79; p<0.05). The 3-year survival rate of patients with peritoneal dissemination was higher in individuals who underwent resection compared with those who did not (9.5 vs. 4.7%, respectively; p<0.001). The current results highlight the improved survival rates of gastric carcinoma patients with non-curative factors who underwent surgery compared with those who did not. Although resection is not curative in this group of patients, we still recommend performing the procedure.
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 8  (4) , 410-415
Clinicopathological features of patients with middle third gastric carcinoma
AIM: To compared the prognosis of middle third gastric carcinoma (MGC) patients with those of patients with proximal/distal gastric carcinoma (PGC/DGC). METHODS: Of 3299 patients diagnosed with gastric carcinoma who underwent surgery at our hospital over a 15-year period, 919 (27.9%) were diagnosed with MGC. For each patient, the following information was obtained from hospital records: Age, sex, tumor size, depth of invasion, histologic type, nodal involvement, extent of lymph node dissection, hepatic metastasis, peritoneal dissemination, stage at initial diagnosis, operative type, curability, and survival rate. RESULTS: T1 category tumors were more common in patients with MGC than in patients with PGC (P < 0.001). Tumor stage (stage I), N category (N0), and T category (T1) significantly influenced the 5-year survival rates for patients with curatively resected tumors. A multivariate analysis showed that age, tumor size, serosal invasion, lymph node metastasis, and curability were significant predictors of survival in patients with MGC. The survival rate for MGC patients was similar to that for PGC/DGC patients (52.8% vs 44.4%/51.4%, P = 0.1138). The 5-year survival rate for MGC patients with curative resection was higher than that for MGC patients with non-curative resection (62.9% vs 8.7%, P < 0.001). CONCLUSION: These results indicate that tumor location did not affect the prognosis. Curative resection is important for improving the prognosis of patients with MGC.
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 8  (4) , 410-415
Open AccessClinicopathological features of patients with middle third gastric carcinoma
AIM: To compared the prognosis of middle third gastric carcinoma (MGC) patients with those of patients with proximal/distal gastric carcinoma (PGC/DGC). METHODS: Of 3299 patients diagnosed with gastric carcinoma who underwent surgery at our hospital over a 15-year period, 919 (27.9%) were diagnosed with MGC. For each patient, the following information was obtained from hospital records: Age, sex, tumor size, depth of invasion, histologic type, nodal involvement, extent of lymph node dissection, hepatic metastasis, peritoneal dissemination, stage at initial diagnosis, operative type, curability, and survival rate. RESULTS: T1 category tumors were more common in patients with MGC than in patients with PGC (P < 0.001). Tumor stage (stage I), N category (N0), and T category (T1) significantly influenced the 5-year survival rates for patients with curatively resected tumors. A multivariate analysis showed that age, tumor size, serosal invasion, lymph node metastasis, and curability were significant predictors of survival in patients with MGC. The survival rate for MGC patients was similar to that for PGC/DGC patients (52.8% vs 44.4%/51.4%, P = 0.1138). The 5-year survival rate for MGC patients with curative resection was higher than that for MGC patients with non-curative resection (62.9% vs 8.7%, P < 0.001). CONCLUSION: These results indicate that tumor location did not affect the prognosis. Curative resection is important for improving the prognosis of patients with MGC.